Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ed Dixon is a member of the firm’s corporate group and is resident in the Washington office.  His practice focuses on the Life Sciences industry.  Mr. Dixon regularly advises pharmaceutical and biotechnology clients on a full range of transactional matters, including complex licensing and collaboration arrangements, acquisitions and divestitures of pharmaceutical companies and products, marketing and co-promotion agreements, and supply and distribution transactions, including authorized generic distribution agreements. 

  • AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals.
  • Eisai in connection with a marketing and supply agreement with Arena Pharmaceuticals, Inc. for the exclusive right to commercialize lorcaserin for obesity and weight management in North and South America.
  • AstraZeneca in connection with its agreement granting Pfizer worldwide rights to sell an OTC version of AstraZeneca’s blockbuster proton pump inhibitor, Nexium. 
  • AstraZeneca in its global collaboration with The Medicines Company to develop and commercialize acute ischemic heart disease compounds.
  • Eli Lilly and Company in supply and distribution arrangements for its radiopharmaceutical PET imaging agent Amyvid™.
  • Eisai in its worldwide collaboration with Epizyme, Inc. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.
  • AstraZeneca in a worldwide collaboration with Targacept, Inc. to develop and commercialize a late-stage investigational product for major depressive disorder.
  • AstraZeneca in its co-promotion arrangements with Abbott for AstraZeneca's Crestor® and Abbott’s Trilipix®.
  • AstraZeneca in its global collaboration with Bristol-Myers Squibb to develop and commercialize the diabetes drugs Onglyza® and Forxiga®.
  • AstraZeneca in its collaboration with Abbott to develop a combination product containing fenofibrate and AstraZeneca’s statin Crestor®. 
  • Merck in its distribution arrangements for authorized generic versions of Zocor® and Proscar®.
  • Washington DC Super Lawyers (2014-2015) 
  • Legal 500 US, Patent: Portfolio Management and Licensing (2016) 
  • Legal 500 US, Healthcare: Life Sciences (2013-2014)
  • LMG Life Sciences, "Life Science Star - Finance & Transactional" (2012-2013)